1. 501 Role of platelet-bound complement activation product (PC4d) in predicting risk of future thrombotic events in systemic lupus erythematosus. (14th December 2022) Authors: Askanase, Anca; Conklin, John; Petri, Michelle; Kyttaris, Vasileios; Gartshteyn, Yevgeniya; Tang, Wei; Kammesheidt, Anja; Alexander, Roberta Vezza Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 3 Page Start: A17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Journal Club: Efficacy and Safety of Voclosporin Versus Placebo for Lupus Nephritis (AURORA 1): A Double‐Blind, Randomized, Multicenter, Placebo‐Controlled, Phase 3 Trial. Issue 12 (31st August 2021) Authors: Rubio, Jose; Kyttaris, Vasileios Journal: ACR open rheumatology Issue: Volume 3:Issue 12(2021) Page Start: 827 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Systemic lupus erythematosus: new molecular targets. (12th October 2007) Authors: Crispín, José C; Kyttaris, Vasileios; Juang, Yuang-Taung; Tsokos, George C Journal: Annals of the rheumatic diseases Issue: Volume 66(2007)Supplement 3 Page Start: iii65 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗